## AMENDMENTS TO THE CLAIMS

1-41 (Canceled)

42. (Previously Presented) An immunostimulatory nucleic acid, having a sequence including at least the following formula:

2

5' TCGTCGTTTTGTCGTTTTGTCGTT 3' (SEQ ID No. 46)

wherein the nucleic acid has less than or equal to 100 nucleotides, and wherein C is unmethylated.

- 43. (Previously Presented) The immunostimulatory nucleic acid of claim 42, wherein at least one nucleotide has a phosphate backbone modification and wherein the phosphate backbone modification is a phosphorothioate or phosphorodithioate modification.
- 44. (Previously Presented) The immunostimulatory nucleic acid of claim 42, wherein at least one nucleotide has a phosphate backbone modification and wherein the phosphate backbone modification occurs at the 5' end of the nucleic acid.
- 45. (Previously Presented) The immunostimulatory nucleic acid of claim 42, wherein at least one nucleotide has a phosphate backbone modification and wherein the phosphate backbone modification occurs at the 3' end of the nucleic acid.

46-50. (Canceled)

51. (Previously Presented) The immunostimulatory nucleic acid of claim 42, wherein the immunostimulatory nucleic acid is less than 40 nucleotides in length.

52-57. (Canceled).

Reply to Office Action of September 21, 2006

58. (Previously Presented) The immunostimulatory nucleic acid of claim 42, wherein the immunostimulatory nucleic acid has a sequence consisting of TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID No. 46).

3

Docket No.: C1039.70077US00

- 59. (Previously Presented) The immunostimulatory nucleic acid of claim 58, wherein each internucleotide linkage has a phosphorothioate modification.
- 60. (Previously Presented) The immunostimulatory nucleic acid of claim 58, further comprising an antigen.
- (Previously Presented) The immunostimulatory nucleic acid of claim 60, wherein 61. the antigen is a vaccine and further comprising a conventional adjuvant.

## (Canceled) 62-73.

(Previously Presented) The immunostimulatory nucleic acid of claim 42, wherein 74. the immunostimulatory nucleic acid is formulated as a composition with a pharmaceutically acceptable carrier.